A multicenter Phase II trial reported that early abundant normal saline after intravenous thrombolysis improved 90-day functional recovery in acute ischemic stroke without increasing mortality or cardiac safety risks. The study adds to the evidence base for post-thrombolysis fluid strategies, an area where practical protocols can vary widely across stroke centers. The trial’s key point for clinicians is the balance between efficacy and safety: improved functional outcomes paired with no signal for additional adverse events. The data will likely influence ongoing discussions about standardized post-thrombolysis care pathways and future larger confirmatory studies.